Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

100.83 -4.14 (-3.94%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
Via The Motley Fool
Where Axsome Therapeutics Stands With Analysts
 
Via Benzinga
FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required
The FDA rejected Axsome's AXS-14 fibromyalgia, prompting a new trial and pushing the expected drug launch to 2028. 
Via Benzinga
Demystifying Axsome Therapeutics: Insights From 11 Analyst Reviews
 
Via Benzinga
Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability
The regulator said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review. 
Via Stocktwits
Topics Stocks
Earnings Scheduled For May 5, 2025
 
Via Benzinga
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)
 
Via Benzinga
2 Soaring Stocks Wth More Upside Potential
Via The Motley Fool
Why Is Teva Stock Trading Higher On Tuesday?
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design. 
Via Benzinga
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
Expert Outlook: Axsome Therapeutics Through The Eyes Of 16 Analysts
 
Via Benzinga
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis
Via The Motley Fool
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years
Via The Motley Fool
3 Monster Stocks in the Making
Via The Motley Fool
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1
Axsome beat Q1 expectations with $121.5 million in revenue and strong Auvelity sales as it prepares Symbravo's U.S. launch and advances key drug programs. 
Via Benzinga
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)
 
Via Benzinga
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Stocks Edge Higher Despite Trade, Economic Jitters
Stocks are modestly higher Tuesday afternoon, as Wall Street shakes off a sluggish open amid a new wave of economic data. 
Via Talk Markets
Topics Stocks / Equities
Why Shares of Axsome Therapeutics Slumped Today
Via The Motley Fool
Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week
The company posted mixed results for its depression treatment, noting it appears to work in a smaller patient group. 
Via Investor's Business Daily
Axsome's Solriamfetol Fails Primary Goal In Depression Study But Shows Improvements In Associated Sleep Disorder
Axsome's Phase 3 trial for solriamfetol in MDD did not meet its primary endpoint, but positive data in severe EDS patients supports plans for a new study in 2025. 
Via Benzinga
Celanese To Rally Around 27%? Here Are 10 Top Analyst Forecasts For Thursday
 
Via Benzinga
Breaking Down Axsome Therapeutics: 31 Analysts Share Their Views
 
Via Benzinga
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
Via The Motley Fool
IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried.
The company is working on a non-stimulant approach to treating ADHD. 
Via Investor's Business Daily
Axsome Therapeutics Lower Dose Of Attention Deficient Disorder Candidate Hits Primary Goal
Axsome's solriamfetol met primary and key secondary endpoints in a Phase 3 ADHD trial, showing significant symptom reduction and a favorable safety profile. 
Via Benzinga
Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs
Axsome's Symbravo outperformed oral CGRP inhibitors in a Phase 3 trial, improving migraine pain relief, symptom control, and return to daily activities. 
Via Benzinga
Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride
CEO Herriot Tabuteau struck an optimistic tone, citing strong commercial growth, a rapidly advancing pipeline, and the recent U.S. approval of Symbravo for migraine treatment. 
Via Stocktwits
US, Russia Begin Ukrainian Peace Talks, Intel Shares Surge: What's Driving Markets Tuesday?
Major U.S. indices are little-changed in Tuesday's midday trading as investors monitor recent geopolitical developments and anticipate the release of the latest FOMC minutes on Wednesday. 
Via Benzinga
Axsome's AXS-05 In Alzheimer's Agitation Could Be Billion Dollar Opportunity, Says Analyst
Axsome Therapeutics reports strong Q4 2024 revenues, driven by increased sales of Auvelity and Sunosi. Anticipated milestones and FDA approval for Symbravo make AXSM a top pick for 2025. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.